Jochem Gokemeijer: Immunogenicity risk assessment tool box for biologics drug development

(41:23)

Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop

(17:30)

Predicting and Taming Immunogenicity: Strategies for your Biologic Drug

(1:5:5)

Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop

(17:3)

Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop

(19:56)

Jochem Geheniau tijdens Real Estate Connect 2013 how to attract the global buyer #icny

(3:46)

Clinical Bioinformatics - Predicting impact of a variant on protein structure

(5:30)

Overcome the Challenges of PK Assay Development Using TrailBlazer Antibodies

(49:1econd)

Webinar - Managing Challenging Bioanalysis for PK/PD assessments for Phase I Biologic

(53:56)

Antibody-drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenge Presentation

(18:42)

Immunogenicity

(12:22)

Anti-Drug Antibodies, Random Drug Levels with Efficacy in Certolizumab Pegol

(21:51)

Priya Sriraman: Measuring Host-vs-CAR-T Immune Responses

(36:23)

Biosimilars: Regulatory Perspective on Pre clinical Pharmacology and Safety Evaluation

(1:11:35)

Immunogenicity Assessment and Clinical Relevance

(4:1econd)

The science of biosimilarity: Immunogenicity

(5:29)

Hearing: Measurement Standards to Facilitate the Research and Development of Biologic Drugs

(52:35)

Clinical relevance of immunogenicity to biologics

(6:41)

Immunogenicity Assessments for Immuno-oncology Drug and Therapy Development

(50:23)

Host Cell Protein (HCP) Coverage Analysis Software - SpotMap 5

(19)

Timothy Hickling: Immunogenicity of biotherapeutics: why do we care and where do we stand

(52:5)

Immunogenicity overview of therapeutic biologics

(13:20)

Katerina Alexaki: Effects of codon optimization on biotherapeutics: Implications for immunogenicity

(31:45)

Jeremy Fry: An integrated approach to managing immunogenicity risk and drug immune modulation

(29:40)